Investor Backing & Capital Strength:
Large late-stage financing, including a $100M Series C in May 2026 that brought total funding to about $215M, signals ample runway and external confidence. Coverage of a valuation step-up around $1.75B and participation from prominent firms reinforces balance-sheet strength.
Strategic Partnerships:
In‑network status with major insurers and expanding relationships with health plans, employers, and health systems are emphasized across recent materials. Access to 160M–200M+ covered lives and significant health‑system referrals indicate robust commercialization channels.
Strong Revenue Growth:
Recognition on the 2026 Inc. 5000 and statements of year‑over‑year acceleration point to rapid top‑line expansion. Directional revenue signals align with sharp increases in patients served and provider capacity.
